Last updated on September 2018

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy

Brief description of study

The purpose of this study is to determine whether Nivolumab+ chemotherapy and Nivolumab+Ipilimumab is effective in the treatment of patients with EGFR mutation, T790M negative NSCLC who failed first line (1L) EGFR TKI therapy

Clinical Study Identifier: NCT02864251

Contact Investigators or Research Sites near you

Start Over

Jessica Bauman, Site 0032

Fox Chase Cancer Center
Philadelphia, PA United States
  Connect »